Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Current Deferred Revenue (2016 - 2024)

Rockwell Medical (RMTI) has disclosed Current Deferred Revenue for 15 consecutive years, with $46000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Deferred Revenue fell 91.17% year-over-year to $46000.0, compared with a TTM value of $46000.0 through Dec 2024, down 91.17%, and an annual FY2024 reading of $46000.0, down 91.17% over the prior year.
  • Current Deferred Revenue was $46000.0 for Q4 2024 at Rockwell Medical, down from $487000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.6 million in Q1 2021 and bottomed at $46000.0 in Q1 2024.
  • Average Current Deferred Revenue over 5 years is $2.4 million, with a median of $2.2 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue skyrocketed 4749.33% in 2022, then tumbled 96.44% in 2023.
  • Year by year, Current Deferred Revenue stood at $2.2 million in 2020, then dropped by 0.18% to $2.2 million in 2021, then surged by 99.49% to $4.3 million in 2022, then crashed by 87.97% to $521000.0 in 2023, then plummeted by 91.17% to $46000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for RMTI at $46000.0 in Q4 2024, $487000.0 in Q3 2024, and $498000.0 in Q2 2024.